- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 11, Issue 12, 2010
Current Drug Targets - Volume 11, Issue 12, 2010
Volume 11, Issue 12, 2010
-
-
Editorial [Hot Topic: Therapeutic Applications of the Heme Oxygenase System (Guest Editor:Stephan Immenschuh)]
More LessThe heme oxygenase (HO) enzyme reaction has initially been described more that 40 years ago [1]. HO catalyzes the degradation of the redox-reactive molecule heme into equimolar amounts of bilirubin, carbon monoxide (CO) and iron. Two genetically distinct isozymes of HO, HO-1 and HO-2, have been identified and exhibit distinct patterns of cell- and tissue- specific gene expression. In contrast to the constitutive isofor Read More
-
-
-
Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Authors: Stefan W. Ryter and Augustine M.K. ChoiAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain major causes of morbidity and mortality in critical care medicine despite advances in therapeutic modalities. ALI can be associated with sepsis, trauma, pharmaceutical or xenobiotic exposures, high oxygen therapy (hyperoxia) and mechanical ventilation. The stress protein heme oxygenase-1 (HO-1) provides an inducible defense mechanism Read More
-
-
-
Regulatory Role of Anesthetics on Heme Oxygenase-1
Authors: Alexander Hoetzel and Rene SchmidtAs an enzyme, heme oxygenase (HO) can provide substantial cellular protection. By eliminating free heme and generating iron, biliverdin, as well as carbon monoxide, HO exerts anti-inflammatory, anti-proliferative, antioxidative, and vasodilatory effects. The inducible form of HO, heme oxygenase-1 (HO-1) can be upregulated by harmful stimuli in most human cell types. In such a way, cells utilize HO-1 as a mechanism of Read More
-
-
-
Targeting Heme Oxygenase-1 in Vascular Disease
More LessHeme oxygenase-1 (HO-1) metabolizes heme to generate carbon monoxide (CO), biliverdin, and iron. Biliverdin is subsequently metabolized to bilirubin by biliverdin reductase. HO-1 has recently emerged as a promising therapeutic target in the treatment of vascular disease. Pharmacological induction or gene transfer of HO-1 ameliorates vascular dysfunction in animal models of atherosclerosis, post-angiopla Read More
-
-
-
Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Authors: Agnieszka Jazwa and Antonio CuadradoHeme oxygenase-1 (HO-1), an enzyme degrading heme to carbon monoxide, free iron, and biliverdin, participates in the cell defence against oxidative stress and it has been speculated that it might be a new therapeutic target for neuroprotection. In this review, we discuss recent findings on the regulation of the HO-1 gene, Hmox1, in the brain with particular focus on the transcription factors Nrf2 and HIF-1. Functional poly Read More
-
-
-
Heme Oxygenase-1 in Lung Disease
Authors: Chintan M. Raval and Patty J. LeeThe lungs are a major target for various inflammatory, oxidative, carcinogenic or infectious stressors, which result in a range of lung diseases. Induction of heme oxygenase-1 (HO-1) during acute and chronic lung processes is a crucial defense mechanism. HO-1 catalyzes the degradation of free cellular heme to iron, carbon monoxide (CO) and biliverdin which is eventually converted to bilirubin by biliverdin reductase. In addit Read More
-
-
-
Heme Oxygenase-1 and Iron in Liver Inflammation: A Complex Alliance
Authors: Stephan Immenschuh, Eveline Baumgart-Vogt and Sebastian MuellerHeme oxygenase (HO)-1 is the inducible isoform of the first and rate-limiting enzyme of heme degradation. HO-1 has potent antioxidant and also anti-inflammatory functions, the underlying mechanisms of which are not well understood. Together with antioxidant carbon monoxide and biliverdin, HO produces reactive iron, which unambiguously connects this enzyme with the iron metabolism and its potential toxicity. A lin Read More
-
-
-
Heme Oxygenase-1 in Tumor Biology and Therapy
Authors: Halina Was, Jozef Dulak and Alicja JozkowiczHeme oxygenase-1 (HO-1) degrades heme to carbon monoxide (CO), biliverdin, and ferrous iron. As HO-1 expression is highly increased by stressful conditions, the major role of the enzyme is the protection against oxidative injury. Additionally, it regulates cell proliferation, modulates inflammatory response and facilitates angiogenesis. Beneficial activities of HO-1 have been recognized in many pathological states e.g. Read More
-
-
-
The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Wound healing is an intricate process requiring the concerted action of keratinocytes, fibroblasts, endothelial cells, and macrophages. Here, we review the literature on normal wound healing and the pathological forms of wound healing, such as hypertrophic or excessive scar formation, with special emphasis on the heme-heme oxygenase (HO) system and the versatile effector molecules that are formed after HO-mediated h Read More
-
-
-
Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
More LessThe range and diversity of functions of biliverdin reductase (BVR) are unmatched by any enzyme characterized to date. BVR is the sole catalyst for the conversion of biliverdin-IXα, the activity product of the stress-inducible HO-1 and the constitutive HO-2, to bilirubin-IXα. Bilirubin is both cytoprotective and cytotoxic, quenches reactive oxygen species (ROS) and inhibits inflammatory and mitogen-induced ROS-mediated re Read More
-
-
-
Interaction of Carbon Monoxide with Transition Metals: Evolutionary Insights into Drug Target Discovery
Authors: Roberta Foresti and Roberto MotterliniThe perception that carbon monoxide (CO) is poisonous and life-threatening for mammalian organisms stems from its intrinsic propensity to bind iron in hemoglobin, a reaction that ultimately leads to impaired oxygen delivery to tissues. From evolutionary and chemical perspectives, however, CO is one of the most essential molecules in the formation of biological components and its interaction with transition metals is at the or Read More
-
-
-
Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Authors: Tetsuya Honda, Yoshiki Tokura, Yoshiki Miyachi and Kenji KabashimaProstanoids, consisting of prostaglandins and thromboxane, are cyclooxygenase metabolites of arachidonic acid released in various pathophysiological conditions which exert a range of actions mediated through their respective receptors expressed on target cells. Although it has been difficult to analyze the physiological role of prostanoids, recent developments in both the disruption of the respective gene and rec Read More
-
-
-
Targeting Trypanothione Metabolism in Trypanosomatid Human Parasites
Authors: Viridiana Olin-Sandoval, Rafael Moreno-Sanchez and Emma SaavedraThe diseases caused by the trypanosomatid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania are widely distributed throughout the world. Because of the toxic side-effects and the economically unviable cost of the currently used pharmaceutical treatments, the search for new drug targets continues. Since the antioxidant metabolism in these parasites relies on trypanothione [T(SH)2], a functional analog of Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
